ข้ามไปที่เนือ้หา
View online Molecular Characterization of the von Hippel-Lindau... แสดงตัวอย่างรายการนี้
ปิดแสดงตัวอย่างรายการนี้
ตรวจสอบ...

Molecular Characterization of the von Hippel-Lindau Ubiquitin Ligase

ผู้แต่ง: Ohh, Michael; Sufan, Roxana Ioana
สำนักพิมพ์: 2009-11 2011-03-08T17:23:04Z WITHHELD_ONE_YEAR 2011-03-08T17:23:04Z 2011-03-08T17:23:04Z
วิทยานิพนธ์: Thesis / Dissertation ETD
ครั้งที่พิมพ์/รูปแบบ:   วิทยานิพนธ์ / ดุษฎีนิพนธ์ : วิทยานิพนธ์ / ดุษฎีนิพนธ์ : หนังสืออีเล็กทรอนิกส์
ฐานข้อมูล:WorldCat
สรุป:
Marking proteins for degradation by the proteasome is a classical function of ubiquitination. This process of covalent attachment of a chain of ubiquitin molecules to target proteins is governed by the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3). The von Hippel-Lindau (VHL) tumour suppressor protein forms an E3 ubiquitin ligase, ECV (Elongins BC/Cul2/VHL),  อ่านมากขึ้น…
คะแนน:

(ยังไม่ให้คะแนน) 0 กับความคิดเห็น - เป็นคนแรก

หัวเรื่อง
เพิ่มเติมเช่นนี้

 

ค้นหาสำเนาออนไลน์

เชื่อมโยงไปยังรายการนี้

ค้นหาสำเนาในห้องสมุด

&AllPage.SpinnerRetrieving; ค้นหาห้องสมุดที่มีรายการนี้

รายละเอียด

ประเภท/แบบฟอร์ม Thesis
ขนิดวัสดุ: วิทยานิพนธ์ / ดุษฎีนิพนธ์, ทรัพยากรอินแทอร์เน็ต
ประเภทเอกสาร แหล่งข้อมูลอินเทอร์เน็ต
ผู้แต่งทั้งหมด : ผู้แต่งร่วม Ohh, Michael; Sufan, Roxana Ioana
OCLC Number: 721252520
หมายเหตุถาษา: en_ca

บทคัดย่อ:

Marking proteins for degradation by the proteasome is a classical function of ubiquitination. This process of covalent attachment of a chain of ubiquitin molecules to target proteins is governed by the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3). The von Hippel-Lindau (VHL) tumour suppressor protein forms an E3 ubiquitin ligase, ECV (Elongins BC/Cul2/VHL), which targets the alpha subunit of hypoxia-inducible factor (HIF) for ubiquitin-mediated destruction under normal oxygen tension. Tumour hypoxia promotes accumulation of HIFalpha, whose expression is associated with cancer progression, poor prognosis and resistance to conventional therapies, thus establishing HIF as a therapeutic target. Notably, VHL is functionally inactivated in VHL disease, a hereditary cancer syndrome characterized by the formation of tumours in multiple organs, as well as in the majority of sporadic clear-cell renal cell carcinomas (CCRCC) and haemangioblastomas. Recently, certain VHL mutations have been shown to cause the congenital disorder Chuvash polycythemia. Work contained in this thesis describes the temporally coordinated activation of the ECV, whereby oxygen-dependent recognition of HIFalpha by VHL triggers Cul2 modification by the ubiquitin-like molecule NEDD8, which enhances ECV ubiquitin ligase activity by recruiting the E2. In addition, the feasibility of 'bio-tailored' enzymes in the treatment of cancer is introduced by creating a bioengineered VHL capable of targeting HIFalpha for degradation irrespective of oxygen tension, which leads to the dramatic inhibition of CCRCC tumour growth and angiogenesis in a xenograft model. Furthermore, a ubiquitin ligase composed of two F-box proteins, VHL and suppressor of cytokine signalling 1 (SOCS1), was identified and shown to be paramount for the negative regulation of erythropoiesis by targeting phosphorylated Janus kinase 2 (JAK2) for ubiquitin-mediated destruction. The malfuncti

รีวิว

ความคิดเห็นผู้ที่ใช้งาน
กำลังค้นคืน รีวิว GoodReads…
ค้นคืน DOGObooks บทวิจารณ์

แท็ก

เป็นคนแรก.

รายการคล้ายกัน

เนื้อรื่อง:(9)

ยืนยันคำขอนี้

คุณอาจะร้องขอรายการนี้แล้. โปรดเลือก ตกลง ถ้าคุณต้องการดำเนินการคำขอนี้ต่อไป.

เชิ่อมโยงข้อมูล


Primary Entity

<http://www.worldcat.org/oclc/721252520> # Molecular Characterization of the von Hippel-Lindau Ubiquitin Ligase
    a schema:CreativeWork, pto:Web_document, bgn:Thesis, schema:Book ;
   bgn:inSupportOf "Thesis / Dissertation ETD" ;
   library:oclcnum "721252520" ;
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/jak2> ; # JAK2
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/ubiquitin> ; # Ubiquitin
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/vhl> ; # VHL
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/ccrcc> ; # CCRCC
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/0307> ; # 0307
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/hif> ; # HIF
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/cullin> ; # Cullin
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/polycythemia> ; # Polycythemia
   schema:about <http://experiment.worldcat.org/entity/work/data/896852330#Thing/nedd8> ; # NEDD8
   schema:contributor <http://experiment.worldcat.org/entity/work/data/896852330#Agent/ohh_michael> ; # Ohh, Michael
   schema:creator <http://experiment.worldcat.org/entity/work/data/896852330#Agent/sufan_roxana_ioana> ; # Sufan, Roxana Ioana
   schema:datePublished "2011/03/08T17:23:04Z" ;
   schema:datePublished "2009/11" ;
   schema:datePublished "WITHHELD_ONE_YEAR" ;
   schema:description "Marking proteins for degradation by the proteasome is a classical function of ubiquitination. This process of covalent attachment of a chain of ubiquitin molecules to target proteins is governed by the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2) and the ubiquitin ligase (E3). The von Hippel-Lindau (VHL) tumour suppressor protein forms an E3 ubiquitin ligase, ECV (Elongins BC/Cul2/VHL), which targets the alpha subunit of hypoxia-inducible factor (HIF) for ubiquitin-mediated destruction under normal oxygen tension. Tumour hypoxia promotes accumulation of HIFalpha, whose expression is associated with cancer progression, poor prognosis and resistance to conventional therapies, thus establishing HIF as a therapeutic target. Notably, VHL is functionally inactivated in VHL disease, a hereditary cancer syndrome characterized by the formation of tumours in multiple organs, as well as in the majority of sporadic clear-cell renal cell carcinomas (CCRCC) and haemangioblastomas. Recently, certain VHL mutations have been shown to cause the congenital disorder Chuvash polycythemia. Work contained in this thesis describes the temporally coordinated activation of the ECV, whereby oxygen-dependent recognition of HIFalpha by VHL triggers Cul2 modification by the ubiquitin-like molecule NEDD8, which enhances ECV ubiquitin ligase activity by recruiting the E2. In addition, the feasibility of 'bio-tailored' enzymes in the treatment of cancer is introduced by creating a bioengineered VHL capable of targeting HIFalpha for degradation irrespective of oxygen tension, which leads to the dramatic inhibition of CCRCC tumour growth and angiogenesis in a xenograft model. Furthermore, a ubiquitin ligase composed of two F-box proteins, VHL and suppressor of cytokine signalling 1 (SOCS1), was identified and shown to be paramount for the negative regulation of erythropoiesis by targeting phosphorylated Janus kinase 2 (JAK2) for ubiquitin-mediated destruction. The malfuncti" ;
   schema:exampleOfWork <http://worldcat.org/entity/work/id/896852330> ;
   schema:genre "Thesis" ;
   schema:name "Molecular Characterization of the von Hippel-Lindau Ubiquitin Ligase" ;
   schema:productID "721252520" ;
   schema:publication <http://www.worldcat.org/title/-/oclc/721252520#PublicationEvent/2009_112011_03_08t17_23_04zwithheld_one_year2011_03_08t17_23_04z2011_03_08t17_23_04z> ;
   schema:url <http://hdl.handle.net/1807/26478> ;
   wdrs:describedby <http://www.worldcat.org/title/-/oclc/721252520> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/896852330#Agent/sufan_roxana_ioana> # Sufan, Roxana Ioana
    a bgn:Agent ;
   schema:name "Sufan, Roxana Ioana" ;
    .


Content-negotiable representations

ปิดหน้าต่าง

กรุณาลงชื่อเข้าสู่ระบบ WorldCat 

ยังไม่มีบัญชีผู้ใช้? คุณสามารถสร้างได้อย่างง่ายดาย สร้างบัญชีผู้ใช้ฟรี.